MDXH · MDxHealth SA
AI read · Neutral
The AI's read
MDxHealth posted a revenue beat ($27.2M) and reaffirmed $110–$115M 2026 sales guidance while aiming to return to positive adjusted EBITDA. The company also eliminated a $10.4M contingent liability and raised $20M, improving its balance sheet. The market ripped the stock roughly 85% on the headlines, so much of the immediate upside looks priced in. Volume trends are mixed: tissue tests rose sequentially 13% but were down 1% year over year, so execution must continue to justify lofty moves. We lean neutral. The beat plus guidance is real, but the gap-up has removed near-term asymmetry until sustained volume and margin progress arrive.